Galapagos NV is to acquire two companies with a presence in cell therapy as it takes steps to broaden its business under new leadership. The Dutch company has reached separate agreements to purchase CellPoint BV, a manufacturing company in the Netherlands, and AboundBio Inc, a US drug discovery company with an antibody library and antibody engineering capabilities.
Galapagos is to pay €125 million upfront for CellPoint, with an additional €100 million in potential milestone payments, and about $14 million for AboundBio. They are the first large business transactions to take place under the company’s new chief executive Paul Stoffels, the former chief scientific officers of Johnson & Johnson Inc. Dr Stoffels became CEO on 1 April, succeeding Onno van de Stolpe, the company’s co-founder. The acquisitions are complementary, and in the case of AboundBio, take Galapagos into new areas of antibody technology.
CellPoint, under a collaboration with the contract research organisation Lonza, has developed technology for delivering CAR T cell therapies to a site of care within one week. The current industry delivery standard is more than a month. This supply model is currently being tested in two Phase 1/2a studies in patients with lymphoma and leukaemia. Separately, AboundBio has capacity to develop a new CAR T cell therapy using its antibody technology to design the chimeric antigen receptor. The goal is to bring three new CAR T cell therapies into the clinic over the next three years.
Galapagos announced the acquisitions on 21 June 2022.
Copyright 2022 Evernow Publishing Ltd